Sotera Health Company Q3 2026 Earnings Call Summary

Sotera Health reported Q3 2026 earnings, with Sterigenics and Nelson Labs driving performance. Nordion saw revenue decline due to cobalt-60 timing. Management noted European market softness. Guidance reaffirmed, with flat Q4 Sterigenics revenue and reduced 2027 CapEx. Nelson Labs' growth expected to moderate. Net leverage improved to 2.9x, leading to a credit rating upgrade. Litigation and FX headwinds noted.

Original reporting
Published Nov 3, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 10:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sotera Health Company Q3 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

Med
01

Why it matters

The earnings call provides fresh guidance on revenue, capex, and leverage, offering traders new data to adjust positions.

02

Market read

The disclosed guidance and demand softness are material for investors tracking healthcare services and sterilization niche.

03

What to watch

Potential upside from upcoming M&A activity in sterilization services not reflected in current guidance.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Sotera Health provides sterilization and lab testing services through its Sterigenics, Nelson Labs, and Nordion units.

Market effects

Sterilization services sector may see broader scrutiny on demand trends in Europe.

European medical‑device market softness could affect related suppliers.

Limited to healthcare services investors; no macro‑wide impact.

Counterpoint

If capex cuts free cash flow, the stock could rally on balance‑sheet strength.

Key entities

  • Sotera Health

    Provider of sterilization and lab testing services.

Related articles

$SHCHighAI 8/10

Sotera Health (SHC) Q3 2026 Earnings Call Transcript

Sotera Health (SHC) reported Q3 2026 revenue growth of 4.4% to $325M and adjusted EBITDA growth of 4% to $171M. Sterigenics grew 8.2%, Nelson Labs 9.2%, and Nordion declined 11.5%. The company reaffirmed its 2026 revenue and adjusted EBITDA outlook, expecting 5.25-6.75% and 5.75-7.25% growth, respectively. Adjusted EBITDA margins expanded sequentially by 100 basis points to 52.5%.

$SHCHighAI 8/10

Why is Sotera Health stock sliding today?

Sotera Health (SHC) shares fell 9.5% despite Q3 2026 earnings beat (EPS $0.29, revenue $324.9M) due to cautious guidance. Revenue declined 12% in the Nordion segment. JPMorgan downgraded to Underweight with a $17 target, and insiders sold 1.29M shares. The S&P 500 and Nasdaq rose, but Sotera's decline was company-specific.

$SHCMed

What Sotera Health (SHC) Said on Its Q3 Earnings Call

Sotera Health (SHC) reported Q3 earnings, noting softness in the European medical-device market. Sterigenics expects 6% constant-currency growth in Q4, while Nelson Labs saw 8.8% revenue growth. Nordion revenue fell 12.4% due to shipment timing. The company reaffirmed its 2026 outlook for 5.25% to 6.75% revenue growth and maintained its adjusted EBITDA forecast.